Induction of Apoptosis by 2-Chloro-2'deoxyadenosine (2-CdA) Alone and In Combination with other Cytotoxic Drugs: Synergistic Effects on Normal and Neoplastic Lymphocytes by Addition of Doxorubicin and Mitoxantrone

References

• Toft N. J., Arends M. J. Apoptosis and necrosis in tumors. In: Martin SJ (ed.), Apoptosis and cancer. Basel: Karger Landes Systems. 1997; 22–44
   Google Scholar
• Rummel M. J., Leimer A., Knuth C, Schadeck-Gressel C, Hossfeld L., Bergmann L., Hoelzer D., Mitrou P. S. 2-chlorodeoxyadenosine (2-CdA) in the treatment of previously untreated low grade Non-Hodgkin's lymphomas. Blood 1997; 90(Suppl. 1)342A
   Google Scholar
• Juliusson G., Liliemark J. Complete remission of B-cell chronic lymphocytic leukemia after oral cladribine. Lancet 1993; 341: 54
   PubMed Web of Science ®Google Scholar
• Kay A. C., Saven A., Carrera C. J., Carson D. A., Thurston D., Beutler E., Piro L. D. 2-chlorodeoxyadenosine treatment of low-grade lymphoma. J. Clin. Oncol. 1992; 10: 371–7
   PubMed Web of Science ®Google Scholar
• Saven A., Emanuele S., Kosty M., Koziol J., Ellison D., Piro L. D. 2-chloro-deoxyadenosine activity in patients with untreated, indolent Non-Hodgkin's lymphoma. Blood 1995; 86: 1710–6
   PubMed Web of Science ®Google Scholar
• Piro L. D., Carrera C. J., Beutler E., Carson D. A. 2-chloro-deoxyadenosine, an effective new agent for the treatment of chronic lymphocylic leukemia. Blood 1988; 72: 1069–77
   PubMed Web of Science ®Google Scholar
• Saven A., Piro L. D. Newer purine analogues for the teatment of hairy cell leukemia. New Engl. J. Med. 1994; 330: 691–7
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Taetle R., Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737–43
   PubMed Web of Science ®Google Scholar
• Petersen A. J., Brown R. D., Gibson J., Pope B., Luo X. F., Schutz L., Wiley J. S., Joshua D. E. Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro. Eur. J. Haematol. 1996; 56: 213–20
   PubMed Web of Science ®Google Scholar
• Avery T. L., Rehg J. E., Lumm W. C., Harwood F. C., San-tana V. M., Blakley R. L. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bro-modeoxyadenosine in drug combinations in mice. Cancer Res. 1989; 49: 4972–8
   PubMed Web of Science ®Google Scholar
• Carrera C. J., Saven A., Piro L. D., Beutler E., Terai C., Carson D. A. 2-CdA chemotherapy triggers programmed cell death in normal and malignant lymphocytes. Adv. Exp. Biol 1991; 15: 309A
   Google Scholar
• Carson D. A., Carrera C. J., Wasson D. J., Yamanaka H. Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes. Adv. Enzyme Regul. 1988; 27: 395
   PubMedGoogle Scholar
• Beutler E. Drug profiles. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952
   PubMed Web of Science ®Google Scholar
• Carson DA., Wasson D. B., Kaye J., Ullman B., Martin D. W., JR, Robins R. K., Montgomery J. A. Deoxycy-tidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L 1210 leukemia in vivo. Proc. Natl. Acad. Sci. 1980; 77: 6865–9
   PubMed Web of Science ®Google Scholar
• Arner E. S. J. On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Leukemia and Lymphnma 1996; 21: 225–31
   PubMed Web of Science ®Google Scholar
• Fabianowska-Majewska K., Tybor K., Duley J., Sim-monds A. The influence of 2-chloro-2'-deoxyade-nosine on metabolism of deoxyadenosine in human primary cns lymphoma. Biochem. Pharm. 1995; 50: 1379–83
   PubMed Web of Science ®Google Scholar
• Kristensen J., Nygren P., Liliemark J., Fridborg H., Kil-lander A., Simonsson B., Öberg G., Larsson R. Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. Leukemia 1994; 8: 1712–7
   PubMed Web of Science ®Google Scholar
• Rabinovitch P. S., Torres R. M., Engel D. Simultaneous cell cycle analysis and two- color surface immunof-luorescence using 7- amino- actinomycin D and single laser excitation: applications to study of cell activation and the cell cycle of murine LY-1 B cells. J. Immunol. 1986; 136: 2769–75
   PubMed Web of Science ®Google Scholar
• Schmid I., Uittenbogaart C. H., Keld B., Giorgi J. V. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytome-try. J. Immunol. Methods 1994; 170: 145–57
   PubMed Web of Science ®Google Scholar
• Lecoeur; H., Gougeon M. Comparative analysis of How cytometric methods for apoptosis quantitation in murine thymocytes and human peripheral lymphocytes from controls and HIV- infected persons. Evidence for interference by granulocytes and erythroeytes. J. Immunol. Methods 1996; 198: 87–99
   PubMed Web of Science ®Google Scholar
• Vermes I., Haanen C., Steffens-Nakken H., Reuteling-sperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods 1995; 184: 39–51
   PubMed Web of Science ®Google Scholar
• Stein J., Hahn A., Rehner G. High-performance liquid chromatographic determination of nicotinic acid and nicotinamide in biological samples applying post-column derivatization resulting in bathmochrome absorption shifts. J. Chmmatogr: B. 1995; 665: 71–8
   PubMed Web of Science ®Google Scholar
• Saven A., Lee T., Kosty M., Piro L. Cladribine and mitoxantrone dose escalation in indolent Non-Hodgkin's lymphoma. J. Clin. Oncol. 1996; 14: 2139–44
   PubMed Web of Science ®Google Scholar
• Bromidge T. J., Turner D. L., Howe D. J., Johnson S. A., Rule S. A. J. In vitro chemosensitivity of chronic lymphocytic leukemia to purine analogues - correlation with clinical course. Leukemia 1998; 12: 1230–35
   PubMed Web of Science ®Google Scholar
• Castejón R., Vargas J. A., Briz M., Berrocal E., Romero Y., Gea-Banacloche J. C., Fernández M. N., Durántez A. Induction of apoptosis by 2-chlorodeoxyadenosine in B cell chronic lymphocytic leukemia. Leukemia 1997; 11: 1253–57
   PubMed Web of Science ®Google Scholar
• Albertioni F., Lindemalm S., Reichelova V., Petterson B., Eriksson S., Juliusson G., Liliemark J. Pharma-cokinetics of Cladribine in plasma and its 5'monophosphate and 5'triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin. Cancer Res. 1998; 4: 653–8
   PubMed Web of Science ®Google Scholar
• Begleiter A., Verburg L., Ashique A., Lee K., Israels L. G., Mowat M., Johnston J. B. Comparison of antitu-mor activities of 2-chlorodeoxyadenosine and 9-b˜-arabi-nosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995; 9: 1875–81
   PubMed Web of Science ®Google Scholar
• Kawasaki H., Carrera C. J., Piro L. D., Saven A., Kipps T. J., Carson D. A. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemothera-peutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81: 597–601
   PubMed Web of Science ®Google Scholar
• Betticher D. C., von Rohr A., Ratschiller D., Hsu Schmitz S.F., Egger T., Sonderegger T., Hermann R., Kroner T., Zulian G. B., Cavalli F., Fey M. F., Cerny T. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade Non-Hodgkin's lymphoma. J. Clin. Oncol. 1998; 16: 850–8
   PubMed Web of Science ®Google Scholar
• Cummings J., Anderson L., Willmott N., Smyth J. F. The molecular pharmacology of doxorubicin in vivo. Eur. J. Cancer 1991; 27: 532–5
   PubMed Web of Science ®Google Scholar
• Faulds D., Balfour J. A., Chrisp P., Langtry H. D. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutical potential in the chemotherapy of cancer. Drugs 1991; 41: 400–49
   PubMed Web of Science ®Google Scholar
• Begleiter A., Wang H., Verburg L., Lee L., Israels L. G., Mowat M. R. A., Johnston J. B. In vitro cytoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia. Leukemia 1996; 10: 1959–65
   PubMed Web of Science ®Google Scholar